A Cure Within: Scientists Unleashing The Immune System to Kill Cancer

Canavan, Neil

ISBN 10: 1621822176 / ISBN 13: 9781621822172

Published by Cold Spring Harbor Laboratory Press, 2017

About this Item

Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Seller Inventory # 00080784374

Bibliographic Details

• Title: A Cure Within: Scientists Unleashing The Immune System to Kill Cancer
• Publisher: Cold Spring Harbor Laboratory Press
• Publication Date: 2017
• Language: English
• ISBN 10: 1621822176
• ISBN 13: 9781621822172
• Binding: Hardcover
• Condition: Very Good

About this title

Synopsis

Includes interviews with 2018 Nobel Prize Winners James Allison and Tasuku Honjo

The way we treat cancer is about to change forever. This revolution--and it is precisely that--was sparked not by the invention of a new drug, but by the evolution of an entirely new way of thinking about and managing cancer. Going forward, doctors will not use pharmaceuticals to attack tumors--not directly. Rather, the oncologist will treat the patient's immune system with a drug, and then the patient will treat the tumor.

Based entirely on interviews with the investigators, this book is the story of the immuno-oncology pioneers. It's a story of failure, resurrection, and success. It's a story about science, it's a story about discovery, and intuition, and cunning. It's a peek into the lives and thoughts of some of the most gifted medical scientists on the planet.

This is not a textbook. This is a life book. This technology will save/is saving lives, and the book celebrates the living, breathing, thinking, charming, arrogant, funny, obstinate, amazing human beings who are making immuno-oncology happen.

"The stories and lives shared in this book show readers the decades of devotion and passion it takes to imagine a better world and then make it happen. If this book motivates even one more similarly talented and visionary investigator to deliver on their promise it would be a wonderful success." -- Clifford A. Hudis, MD, FACP, FASCO
Chief Executive Officer, American Society of Clinical Oncology

About the Author

Neil Canavan is a veteran journalist specializing in science and medicine, a career he embarked upon after earning a master's degree in molecular and cellular biodynamics from Rutgers University. With more than 15 years of reporting experience, and some 200 feature articles to his credit Neil has written for such news outlets as WebMD, Medscape, Drug Discovery and Development Magazine, and The Scientist. Currently, Neil is a contributing editor to The Oncology Business Review where he has written many articles on the technology of, and clinical outcomes for cancer immunotherapy.

Since 2014 Neil has held the position of Scientific Advisor at The Trout Group, a New York-based investor relations firm focused on healthcare biotechnology. The Trout Group has 30 clients in the oncology space, with many of those companies pursuing the development of cancer immunotherapies.